Kymera Therapeutics (KYMR) Jumps 10.2% in a Month—Is Wall Street Pricing in a Major 2026 Breakout?
Kymera Therapeutics Inc. (NASDAQ:KYMR), a publicly traded biotechnology company, was founded to pioneer the rapidly expanding field of…
Biodexa Pharmaceuticals (BDRX) Launches Phase 3 Trial for eRapa — Can This $2.81M Biotech Transform FAP Treatment?
Biodexa Pharmaceuticals PLC (NASDAQ:BDRX) is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for diseases with significant…
Galectin Therapeutics (GALT) Surges 10.5% After Insider Sells 120,000 Shares
Galectin Therapeutics Inc. (NASDAQ:GALT) is a clinical-stage biopharmaceutical company focused on developing innovative therapies for fibrotic disease, cancer,…
Analysts Boost Target to $24 as Ocular Therapeutix (OCUL) Nears Major Catalyst
Ocular Therapeutix, Inc. is a biotechnology company dedicated to transforming the treatment landscape for serious ocular diseases through…
Enveric Biosciences (ENVB) Reports Breakthrough PTSD Results as EB-003 Moves Toward IND in 2026
Enveric Biosciences Inc (NASDAQ:ENVB) is a biotechnology company built on a scientific foundation of developing next-generation neuroplastogenic therapeutics…
Sensei Biotherapeutics (SNSE) Cuts Workforce by 65% as It Prepares for a Potential Sale—Is a Major Buyout Coming?
Sensei Biotherapeutics Inc (NASDAQ:SNSE) is a clinical stage biotechnology company built on a foundation of innovative cancer research…
Viking Therapeutics (VKTX) Surges After 78% of Patients Achieve Normal Glycemic Control in Obesity Trial
Viking Therapeutics Inc. (NASDAQ:VKTX) is a clinical-stage biotechnology company dedicated to developing innovative therapies for metabolic disorders, obesity,…
Biodexa Pharmaceuticals (BDRX) Launches Phase 3 Trial for eRapa — Can This $2.8M Biotech Deliver a Breakthrough?
Biodexa Pharmaceuticals Plc (NASDAQ:BDRX) is a clinical-stage biopharmaceutical company operating within the biotechnology industry and focused on discovering,…
West Pharmaceutical Services (WST) Could Outperform as Analysts Project $350.77 Price Target
West Pharmaceutical Services Inc. (NYSE:WST) is one of the most established and influential companies in the global pharmaceutical…
Don’t Let the 70.7% YTD Jump Fool You—Axsome Therapeutics (AXSM) Still Faces Massive Downside Risk
Axsome Therapeutics (NASDAQ:AXSM) is a clinical-stage biopharmaceutical company that has grown into one of the most closely watched…
TG Therapeutics (TGTX) Reports Explosive Q3 Revenue Surge to $161.7M as BRIUMVI Dominates MS Market
TG Therapeutics Inc. (NASDAQ:TGTX) is a biopharmaceutical company built on a vision to transform the treatment landscape for…
Abbott Laboratories (ABT) Posts Stunning 21% EPS Growth—Is This the Strongest Healthcare Stock of 2025?
Abbott Laboratories(NYSE:ABT) is one of the most established and influential healthcare companies in the world, with a history…
Fennec Pharmaceuticals (FENC) Reveals Stunning Japan Trial Data—Hearing Loss Drops from 63% to Just 24%
Fennec Pharmaceuticals (NASDAQ:FENC) is a specialty pharmaceutical company built on the mission of addressing one of the most…
JANUX Therapeutics Just Hit Its Lowest Price Since 2024 — Here’s Why Wall Street Is Still Bullish
Janux Therapeutics is a clinical-stage biotechnology company built on the vision of transforming cancer treatment through next-generation, tumor-activated…
Acadia Healthcare (ACHC) Faces 168% Spike in Claims — Investors Ask: Panic or Massive Buying Opportunity?
Acadia Healthcare Company has grown into one of the largest and most influential behavioral health systems in the…
Astera Labs (ALAB) Surges as New NVLink Fusion Breakthrough Redefines AI Infrastructure
Astera Labs (NASDAQ:ALAB) was founded with a singular vision: to solve one of the most fundamental bottlenecks in…
CVS Health (CVS) Skyrockets 27% in 6 Months as MBR Hits 92.8%
CVS Health Corporation (NYSE:CVS) has evolved into one of the most influential and vertically integrated healthcare companies in…
Tenax Therapeutics (TENX) Sets 2026 Catalyst With 230-Patient Phase 3 Completion Target
Tenax Therapeutics (NASDAQ:TENX) is a late-stage, development-focused biopharmaceutical company built on a long-standing mission to address some of…